GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar

39th Annual J.P. Morgan Healthcare Conference – Virtual

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital

Bryan Garnier European Healthcare Conference 2020 – virtual event

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

Eyecelerator 2020 – Virtual Conference

GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

BioEurope – Digital